SAN ANTONIO, April 9 (UPI) — U.S. researchers say they are testing a viral therapy for a lethal lung cancer.
Researchers at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio have begun enrolling up to 55 patients with squamous non-small cell lung cancer for a clinical trial of the viral treatment — Reolysin — used in combination with two chemotherapy drugs.
“The study offers new hope for this group of patients with lung cancer,” Dr. Alain Mita said in a statement.
Reolysin, an experimental treatment derived from a reovirus that replicates so prolifically in a cancer cell it causes the cell to burst, directly kills many types of cancer cells but leaves normal cells unharmed and works synergistically with other cancer therapies.
The trial — part of a broad collaboration with Oncolytics Biotech Inc., a cancer pharmaceuticals company based in Calgary, Alberta — is one of a group of five phase 2 studies.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.